B2 receptor blockage prevents Aβ-induced cognitive impairment by neuroinflammation inhibition

Behavioural Brain Research

Volumn 278, Issue , 2015, Pages 482-491

  Bicca, M A ^a   Costa, R ^a,b   Loch Neckel, G ^a   Figueiredo, C P ^a,b   Medeiros, R ^a   Calixto, J B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Alzheimer's disease; Amyloid beta; B2 receptor; Kinins; Neuroinflammation

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; AMYLOID BETA PROTEIN; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; CYCLOOXYGENASE 2; ICATIBANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEURONAL NITRIC OXIDE SYNTHASE; NPC 18688; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN[1-40]; BRADYKININ; IMIDAZOLE DERIVATIVE; PEPTIDE FRAGMENT; PTGS2 PROTEIN, MOUSE; SPIRO COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIORAL SCIENCE; CELL ACTIVATION; COGNITIVE DEFECT; DRUG SELECTIVITY; ENZYME INHIBITION; EXPERIMENTAL COGNITIVE TEST; IMMUNOHISTOCHEMISTRY; MALE; MEMORY DISORDER; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; RECEPTOR BLOCKING; TRANSCRIPTION TERMINATION; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; BRAIN CORTEX; CHEMICALLY INDUCED; COGNITION DISORDERS; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; HIPPOCAMPUS; METABOLISM; SPATIAL MEMORY; TIME; UPREGULATION;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONISTS; CEREBRAL CORTEX; COGNITION DISORDERS; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HIPPOCAMPUS; IMIDAZOLES; MALE; MICE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDE FRAGMENTS; SPATIAL MEMORY; SPIRO COMPOUNDS; TIME FACTORS; UP-REGULATION;

EID: 84911164999     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.10.040     Document Type: Article

References (36)

1. Marceau F., Hess J.F., Bachvarov D.R. The B1 receptors for kinins. Pharmacol Rev 1998, 50:357-386.
2. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980, 32:1-46.
3. Calixto J.B., Cabrini D.A., Ferreira J., Campos M.M. Kinins in pain and inflammation. Pain 2000, 87:1-5.
4. Calixto J.B., Medeiros R., Fernandes E.S., Ferreira J., Cabrini D.A., Campos M.M. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004, 143:803-818.
5. Huang H.M., Lin T.A., Sun G.Y., Gibson G.E. Increased inositol 1,4,5-trisphosphate accumulation correlates with an up-regulation of bradykinin receptors in Alzheimer's disease. J Neurochem 1995, 64:761-766.
6. Jong Y.J., Ford S.R., Seehra K., Malave V.B., Baenziger N.L. Alzheimer's disease skin fibroblasts selectively express a bradykinin signaling pathway mediating tau protein. Ser phosphorylation. FASEB J 2003, 17:2319-2321.
7. Viel T.A., Buck H.S. Kallikrein-kinin system mediated inflammation in Alzheimer's disease in vivo. Curr Alzheimer Res 2011, 8:59-66.
8. Selkoe D.J. Alzheimer's disease. Cold Spring Harb Perspect Biol 2011, 3:a004457.
9. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
10. Jong Y.J., Dalemar L.R., Seehra K., Baenziger N.L. Bradykinin receptor modulation in cellular models of aging and Alzheimer's disease. Int Immunopharmacol 2002, 2:1833-1840.
11. Viel T.A., Lima Caetano A., Nasello A.G., Lancelotti C.L., Nunes V.A., Araujo M.S., et al. Increases of kinin B1 and B2 receptors binding sites after brain infusion of amyloid-beta 1-40 peptide in rats. Neurobiol Aging 2008, 29:1805-1814.
12. Prediger R.D., Medeiros R., Pandolfo P., Duarte F.S., Passos G.F., Pesquero J.B., et al. Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease. Neuroscience 2008, 151:631-643.
13. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007, 8:499-509.
14. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
15. Passos G.F., Figueiredo C.P., Prediger R.D., Pandolfo P., Duarte F.S., Medeiros R., et al. Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. Am J Pathol 2009, 175:1586-1597.
16. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 2007, 27:5394-5404.
17. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
18. Medeiros R., Figueiredo C.P., Pandolfo P., Duarte F.S., Prediger R.D., Passos G.F., et al. The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behav Brain Res 2010, 209:165-173.
19. Zhu X., Lee H.G., Raina A.K., Perry G., Smith M.A. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 2001, 11:270-281.
20. Passos G.F., Figueiredo C.P., Prediger R.D., Silva K.A., Siqueira J.M., Duarte F.S., et al. Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. Brain Behav Immun 2010, 24:493-501.
21. Laursen S.E., Belknap J.K. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 1986, 16:355-357.
22. Gobeil F., Montagne M., Inamura N., Regoli D. Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657). Immunopharmacology 1999, 43:179-185.
23. Bicca M.A., Figueiredo C.P., Piermartiri T.C., Meotti F.C., Bouzon Z.L., Tasca C.I., et al. The selective and competitive N-methyl-d-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity induced by amyloid-beta in mice. Neuroscience 2011, 192:631-641.
24. Thinus-Blanc C., Save E., Rossi-Arnaud C., Tozzi A., Ammassari-Teule M. The differences shown by C57BL/6 and DBA/2 inbred mice in detecting spatial novelty are subserved by a different hippocampal and parietal cortex interplay. Behav Brain Res 1996, 80:33-40.
25. Santos D.B., Peres K.C., Ribeiro R.P., Colle D., dos Santos A.A., Moreira E.L., et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid beta peptide in mice. Exp Neurol 2012, 233:767-775.
26. Meotti F.C., Campos R., da Silva K., Paszcuk A.F., Costa R., Calixto J.B. Inflammatory muscle pain is dependent on the activation of kinin B1 and B2 receptors and intracellular kinase pathway. Br J Pharmacol 2012, 166:1127-1139.
27. Gouras G.K., Tampellini D., Takahashi R.H., Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 2010, 119:523-541.
28. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
29. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005, 18:315-321.
30. Figueiredo C.P., Bicca M.A., Latini A., Prediger R.D., Medeiros R., Calixto J.B. Folic acid plus a-tocopherol mitigates amyloid-b-induced neurotoxicity through modulation of mitochondrial complexes activity. J Alzheimers Dis 2011, 24:61-75.
31. McGeer P.L., McGeer E.G. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002, 8:529-538.
32. Xu J., Chen S., Ahmed S.H., Chen H., Ku G., Goldberg M.P., et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 2001, 21:RC118.
33. Noda M., Kariura Y., Amano T., Manago Y., Nishikawa K., Aoki S., et al. Expression and function of bradykinin receptors in microglia. Life Sci 2003, 72:1573-1581.
34. Giovannini M.G., Cerbai F., Bellucci A., Melani C., Grossi C., Bartolozzi C., et al. Differential activation of mitogen-activated protein kinase signalling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer's disease. Neuroscience 2008, 153:618-633.
35. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
36. Lemos M.T., Amaral F.A., Dong K.E., Bittencourt M.F., Caetano A.L., Pesquero J.B., et al. Role of kinin B1 and B2 receptors in memory consolidation during the aging process of mice. Neuropeptides 2010, 42:163-168.